Glioma

This is a general term for a group of brain tumors that start in the glial cells, which support nerve cells. Gliomas can be benign (non-cancerous) or malignant (cancerous).

Condition

What people with Glioma report

Every report comes from a Lived member, sent anonymously.

Have you had Craniotomy for Glioma?

NameHow it went

About Glioma

What It Is

A glioma is a tumor that starts in the brain or spinal cord from glial cells, the cells that support and protect nerve cells. Gliomas are primary tumors, meaning they begin in the nervous system rather than spreading there from cancer elsewhere in the body. They make up a little over one in five of all tumors that start in the brain and spinal cord, and they include glioblastoma, the most common malignant primary brain tumor in adults. Glioma is an umbrella term rather than a single disease. Doctors name each glioma by the kind of cell it resembles, such as an astrocytoma, oligodendroglioma or ependymoma, and give it a grade from 1 to 4. Grade 1 and 2 tumors (low grade) tend to grow slowly, while grade 3 and 4 tumors (high grade) grow quickly. Many gliomas, including some slow-growing ones, spread microscopically into the surrounding brain, which is why they are hard to remove completely and often come back. They rarely spread outside the brain and spinal cord. Symptoms depend on where the tumor sits and how fast it grows. A first seizure is a common way a glioma comes to attention. Other symptoms include headaches (often worse in the morning or eased by vomiting), nausea, weakness or numbness on one side of the body, trouble speaking or finding words, vision changes, problems with memory or concentration, and changes in personality or mood.

Causes & Risk Factors

Gliomas develop when genetic changes build up in glial cells and make them grow out of control. In most people there is no identifiable reason those changes happened, and nothing the person did caused the tumor. There is no known way to prevent gliomas. A few factors raise risk. Gliomas are most often diagnosed in adults over 65 and in children under 12, though slower-growing IDH-mutant gliomas are most common in younger adults, and they are more common in men than in women. Past exposure to radiation is one of the few known outside risk factors. A small share of gliomas occur in people with inherited conditions such as neurofibromatosis type 1, tuberous sclerosis, Li-Fraumeni syndrome or Lynch syndrome. When several relatives have had brain tumors or related cancers, genetic counseling can help decide whether testing makes sense.

How It's Diagnosed

Evaluation usually starts with a neurological exam, which checks strength, sensation, coordination, reflexes, vision, speech and thinking. Magnetic resonance imaging (MRI) of the brain, typically with an injected contrast dye that makes tumors stand out, is the main imaging test; a computed tomography (CT) scan is used when MRI is not possible. Imaging shows where a tumor is and how large it is, but on its own it can misjudge how aggressive a tumor is. The diagnosis is confirmed by examining tumor tissue, taken either with a needle biopsy or during surgery to remove as much of the tumor as is safe. A pathologist studies the cells under a microscope and tests them for specific gene changes, which now define the diagnosis itself. The most important is a change in a gene called IDH (isocitrate dehydrogenase). Glioblastoma lacks it, while IDH-mutant astrocytomas and oligodendrogliomas carry it and generally have a much better outlook. Oligodendrogliomas also show a loss of parts of chromosomes 1 and 19, called 1p/19q codeletion. In glioblastoma, MGMT methylation is a chemical change that switches off a DNA repair gene called MGMT. With that gene silenced, the tumor is less able to repair the damage caused by the chemotherapy drug temozolomide, so this marker helps predict how well temozolomide will work. The final report combines the tumor type, grade and these markers, and it shapes nearly every later decision. When a tumor sits where a biopsy would be too risky, doctors may have to rely on imaging alone.

Treatment Options

Treatment is planned by a team that usually includes a neurosurgeon, a radiation oncologist and a neuro-oncologist. It depends on the tumor's type, grade, molecular markers and location, and on the person's age and overall condition. Because complete removal is rarely possible, surgery alone seldom cures a glioma, so the aim is usually to control the tumor for as long as possible while protecting function and quality of life. Surgery is often the first step. The surgeon removes as much tumor as can be taken out without causing new lasting problems with movement, speech or thinking. When a tumor is near language or movement areas, part of the operation may be done with the person awake so those areas can be mapped and protected. Removing more tumor is linked with better outcomes, but preserving neurological function comes first. For glioblastoma, the standard approach for people who are well enough is about six weeks of radiation given together with daily temozolomide (Temodar), an oral chemotherapy, followed by six more cycles of temozolomide taken five days out of every four weeks. The main side effect to watch is a drop in blood counts, especially platelets, which is checked with regular blood tests. Temozolomide helps most when the tumor has MGMT methylation and much less when it does not. Some people add tumor treating fields, a portable device that delivers low-intensity electric fields through patches on the shaved scalp for at least 18 hours a day. In a large trial it lengthened survival when added to temozolomide, but it takes daily commitment and often irritates the skin. Older or less fit adults may receive a shorter course of radiation, radiation alone, or temozolomide alone when the tumor has MGMT methylation. For IDH-mutant astrocytomas and oligodendrogliomas, the choices are broader. After surgery, some people with low-grade tumors, particularly younger people whose tumor was fully removed, can be watched with regular MRI scans and start further treatment only when needed, which postpones the long-term effects of radiation and chemotherapy. Others receive radiation followed by chemotherapy, often a three-drug combination called PCV (procarbazine, lomustine and vincristine) or temozolomide. In one major trial of higher-risk grade 2 gliomas, adding PCV to radiation raised median survival (the point at which half of people were still alive) from about 8 years to about 13 years. Vorasidenib (Voranigo), a daily pill that blocks the abnormal IDH enzyme, was approved in 2024 for grade 2 IDH-mutant astrocytoma or oligodendroglioma after surgery in people 12 and older. It lengthened the time before the tumor grew again compared with a placebo; whether it extends overall survival is not yet known. It requires regular liver blood tests, because it can cause serious liver injury, and it can harm a pregnancy, so contraception needs to be discussed with the prescriber. Supportive treatment matters at every stage. Corticosteroids reduce brain swelling that causes symptoms, but they are kept to the lowest dose for the shortest time because of their side effects with long-term use. Anti-seizure medicines are used for people who have had a seizure; they are not given to prevent a first one, since that has not been shown to help. When a glioma comes back, options can include another operation, more radiation, a different chemotherapy or a clinical trial. Bevacizumab (Avastin), approved for recurrent glioblastoma, can shrink the tumor for a time in some people and help some lower their steroid dose, but it has not been shown to extend survival. Physical, occupational and speech therapy, psychological support, and palliative care, which focuses on symptoms and quality of life alongside cancer treatment, all have a place from diagnosis onward. Gliomas in children are often low grade and are treated somewhat differently, with particular attention to long-term effects on the developing brain.

What to Expect

Outlook varies widely across gliomas, so the specific diagnosis matters far more than general statistics. Many people with IDH-mutant low-grade gliomas live for many years, and in some groups median survival has exceeded a decade. Even so, these tumors usually grow again at some point, sometimes many years later, and can become higher grade over time. Glioblastoma is much harder to control: in large treatment trials, median survival has been roughly 12 to 18 months, longer for tumors with MGMT methylation, and some people live considerably longer. Younger age and being able to manage daily activities well at diagnosis are linked with better outcomes. Treatment shapes daily life for a time. Radiation means weekday visits for several weeks, fatigue often builds during the course, and hair is usually lost where radiation is aimed. Chemotherapy brings regular blood tests and a higher risk of infection. Some people have lasting changes in memory, concentration, word-finding, mood or energy from the tumor or its treatment. Rehabilitation can help people regain function and adapt work and daily routines. Follow-up relies on MRI scans, usually every few months after treatment and less often when the tumor stays stable. Scans in the first months after radiation can be hard to interpret, because treatment-related changes, called pseudoprogression, can look like tumor growth; doctors sometimes repeat a scan after a short interval before changing course. Because thinking and decision-making can be affected, it helps to talk early about care preferences and choose someone to make medical decisions if needed. Caregivers often carry much of the load, and support groups and counseling can help both the person and their family.

When to Seek Help

Seek prompt medical evaluation when neurological symptoms like those described above are new and keep worsening over days or weeks. They have many possible causes besides a tumor, but they deserve assessment. During treatment, contact your care team promptly about a fever or other signs of infection, unusual bruising or bleeding while taking chemotherapy, or a noticeable worsening of headache, drowsiness, confusion or weakness, which can reflect swelling or tumor growth. Call 911 for a first-ever seizure, which needs same-day emergency assessment. Also call 911 for a seizure that lasts longer than 5 minutes, for repeated seizures without waking up in between, or when the person does not wake up or return to normal behavior after a seizure. Call 911 as well for a sudden, severe headache, sudden new weakness, trouble speaking or vision loss, or if the person becomes very hard to wake.

Questions to Ask Your Doctor

  1. 1.What type and grade is my tumor, and what did the molecular tests such as IDH, 1p/19q and MGMT show?
  2. 2.What are the realistic goals of treatment for my tumor, and what would waiting and monitoring mean instead?
  3. 3.How might surgery, radiation or chemotherapy affect my speech, memory, movement or ability to work?
  4. 4.Is there a clinical trial or a specialized brain tumor center I should consider?
  5. 5.What changes should prompt a call between scans, and whom should I call?

Last reviewed • Oct 2026

Educational content, not medical advice.